The stock of EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) decreased by -$0.2 on Friday to finish at $11.31, down -1.74 percent. The last five days have seen an average of 916,900 shares of common stock traded. 21 times new highs were reached in the current year, with a gain of $7.81. The average number of shares traded over the last 20 days was 677,865, while the average volume over the last 50 days totaled 623,148.
EYPT stock appreciated 7.71% since last month. On 07/26/23, the company’s shares reached a one-month low of $10.01. The stock touched a high of $15.63 on 08/21/23, after rallying from a low of $2.19 in 52 weeks. The price of EYPT stock has risen by 223.14% or $7.81 this year, reaching a new high 21 times. Still, the stock price is down -27.62% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
EYPT stock investors should be aware that EyePoint Pharmaceuticals Inc. (EYPT) stock had its last reported insider trading activity 5 days ago on Aug 23. On Aug 23, 10% Owner EW Healthcare Partners, L.P. sold 121,103 shares at $13.05 each. This transaction resulted in the insider making $1,580,915. On Aug 22, EW Healthcare Partners, L.P. sold 46,778 shares at a price of US$14.62. After the transaction, the insider now owns 4,144,143 shares. Director Liu Ye had earlier sold 1 shares on May 30 for $6.00 a share. The transaction was completed for $6.
Valuation Metrics
Beta for the stock is 1.32. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 10.80, the price-to-book (PB) ratio of 7.44, and the price-to-cash flow ratio of 34.13.
Financial Health
For the three months ended June 29, EyePoint Pharmaceuticals Inc.’s quick ratio was 2.40, while its current ratio was 2.40, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 80.60% percent. Based on annual data, it had gross profit of $33.08 million and revenue of $41.4 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. EYPT’s return on assets (ROA) during the last 12 months has been -58.00%. There was a -74.30% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -115.10%.
Earnings Surprise
According to EyePoint Pharmaceuticals Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $9.11 million, while revenues fell by -27.0% to $7.68 million. It was predicted that EyePoint Pharmaceuticals Inc.’s quarterly earnings would be -$0.61, but it ended up being $0.6, beating the consensus by -201.70%. EBITDA was -$22.68 million for the quarter. At the end of EyePoint Pharmaceuticals Inc.’s most recent quarter ended June 29, its liabilities totaled 118.39 million, while its total debt was $6.42 million. Equity owned by shareholders amounts to $34.98 million.
Technical Picture
Here’s a quick look at EyePoint Pharmaceuticals Inc.’s (EYPT) price momentum from a technical perspective. As of 25 August, the RSI 9-day stood at 36.13%, suggesting the stock is Neutral, with a 131.29% historical volatility rate.
The stochastic %K and %D were 18.15% and 37.94% respectively, while the average true range (ATR) was 1.45. Based on the 14-day stochastic reading of 21.75%, the RSI (14) reading is 43.40%. On the 9-day MACD Oscillator, the stock is at -1.84, and the 14-day reading is at -1.93.
Analyst Ratings
In its analyst report released on April 21, 2023, Robert W. Baird began covering EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT). The stock was rated as an Outperform by the brokerage firm. Analysts have assigned EyePoint Pharmaceuticals Inc. (EYPT) an Buy rating. EYPT is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 1 rate it overweight and 7 others recommend it as a buy.
What is EYPT’s price target for the next 12 months?
The current consensus forecast for the stock is between $22.00 and $55.00, with a median target price of $30.00. In analyzing these forecasts, the average price target given by analysts for EyePoint Pharmaceuticals Inc. (EYPT) is $31.75.
